DMAC today
$9.66-$0.01 (-0.10%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourDescending Triangle
1 hourLeaning Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $7.53
Key levels
Resistance$10.42
Support$9.04
Support$8.29
Latest news & SEC filings
ProductDiaMedica Therapeutics hits enrollment milestone in Phase 2/3 DM199 stroke trial
ProductDiaMedica Therapeutics reaches 200 participants in stroke study
All DMAC news →About DiaMedica Therapeutics
DiaMedica Therapeutics is a drug developer focused on serious conditions caused by restricted blood flow. Its main candidate, DM199, is a lab-made version of the human KLK1 protein and is being tested in women with preeclampsia or fetal growth restriction and in patients who have suffered an acute ischemic stroke. A second, earlier program, DM300, is a modified ulinastatin under study for inflammation of the pancreas. Trials run at sites in South Africa, North America, the United Kingdom and elsewhere.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
DiaMedica Therapeutics Inc. (DMAC)
What Is the Price Target for DMAC?
SEPT Low Target
$12.00
SEPT Mid Target
$12.00
SEPT High Target
$12.00
Analyst Consensus
$12.00
Is DMAC a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DMAC.
Start Free Trial →Is DMAC Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
Analyst Consensus
Fair Value
$12.00
0
Moat Score
NONE
2/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with DMAC?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →DMAC Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
-31.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for DMAC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for DMAC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:55:09 | $9.69 | 4,813 | $$47K | SELL |
| 17:57:35 | $9.74 | 2,000 | $$19K | SELL |
| 17:48:05 | $9.78 | 1,500 | $$15K | BUY |
| 17:26:38 | $9.78 | 1,000 | $$10K | BUY |
| 16:11:01 | $9.64 | 1,000 | $$10K | MIDPOINT |
5 dark pool trades shown · $$100K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for DiaMedica Therapeutics Inc. (DMAC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →DMAC — frequently asked questions
What is DMAC stock price today?
DiaMedica Therapeutics Inc. (DMAC) is at $9.66, down 0.10% (-$0.01) at the Nov 11, 2026 close.
Why is DMAC stock moving today?
Latest DMAC news — Oct 23, 2026: DiaMedica Therapeutics hits enrollment milestone in Phase 2/3 DM199 stroke trial · Oct 22, 2026: DiaMedica Therapeutics reaches 200 participants in stroke study
What is the DMAC price target?
The average analyst price target for DMAC is $12.00, ranging from $12 to $12, based on 1 analysts.
What do analysts rate DMAC?
Analyst ratings for DMAC: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did DMAC beat earnings?
DMAC last reported on Aug 10, 2026: EPS -$0.19 vs -$0.20 expected — a beat of 5.4%.
Does DMAC pay a dividend?
DMAC does not currently pay a dividend.
What are DMAC support and resistance levels?
Support: $9.04, $8.29, $7.53. Resistance: $10.42.
What are insiders doing with DMAC?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on DMAC?
Oct 23, 2026: DiaMedica Therapeutics hits enrollment milestone in Phase 2/3 DM199 stroke trial · Oct 22, 2026: DiaMedica Therapeutics reaches 200 participants in stroke study